Aducanumab is a human monoclonal immunoglobulin (Ig) G1 antibody that selectively targets amyloid-β aggregates and clears amyloid plaques from the brain via a microglia-mediated phagocytic process, indicated in the treatment of Alzheimer's disease. The medication was controversially approved by the FDA in 2021 despite concerns about the questionable study outcomes.